tiprankstipranks
Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update
Company Announcements

Reviva Pharmaceuticals Progresses with Brilaroxazine Study Update

Pick the best stocks and maximize your portfolio:

An announcement from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available.

Reviva Pharmaceuticals announced an enrollment update for its open-label extension study on brilaroxazine, showcasing promising results in schizophrenia patients. With 108 patients completing a year of treatment, the trial indicates good tolerability and supports the drug’s New Drug Application submission to the FDA. The study is on track to provide crucial long-term safety data by early 2025, with top-line results expected by December 2024.

See more data about RVPH stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskReviva Pharmaceuticals Strengthens Financial Position with Offering
TheFlyReviva Pharmaceuticals 12M share Spot Secondary priced at $1.50
TheFlyReviva Pharmaceuticals announces common stock, warrant offering, no amount given
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App